Login
$VXRT
$0.32 +$0.00 (0.0%) Close

$VXRT SEC Filings

Filed On Filing
05 Nov 2026 FORM 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Topline data from 400-person sentinel safety cohort and approximately 5,000 patients in main cohort Phase 2b COVID-19 trial anticipated by mid-year 2027

20 Oct 2026 Form 4: Bono Raquel C., Director

Received 78,800 shares as a grant or award · Granted 157,400 Stock Option (right to buy)

20 Oct 2026 Form 3: Bono Raquel C., Director

No securities owned

19 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Board-certified surgeon and former Director of the Defense Health Agency brings extensive leadership, public health and governance experience

14 Sep 2026 8-K: Other Events

On September 3, 2026, the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”), approved a Director Resignation Policy that requires a director, following certification of the stockholder vote from the meeting at which the el...

25 Aug 2026 8-K: Other Events

On August 21, 2026, the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”), upon the recommendation of the Nominating and Governance Committee, formed two new committees of the Board: the Clinical and Regulatory Affairs Com...

06 Aug 2026 FORM 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

Reported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety cohort and approximately 5,000 participants in main cohort anticipated in first half of 2027

28 Jul 2026 8-K: Other Events

On July 27, 2026, upon the recommendation of the Nominating and Governance Committee, the Board of Directors of Vaxart, Inc. (the “Board”) approved the reorganization of its Nominating and Governance Committee and the Compensation Commit...

20 Jul 2026 Form 4: Finney Kevin, Director

Received 39,400 shares as a grant or award · Granted 78,700 Stock Options (right to buy)

17 Jul 2026 Form 4: Breitmeyer James B, Director

Received 8,315 shares as a grant or award · Granted 16,610 Stock Options (right to buy)

17 Jul 2026 Form 4: Heron Elaine J, Director

Received 39,400 shares as a grant or award · Granted 78,700 Stock Options (right to buy)

17 Jul 2026 Form 4: Watson W. Mark, Director

Received 39,400 shares as a grant or award · Granted 78,700 Stock Options (right to buy)

17 Jul 2026 Form 4: Wheadon David E., Director

Received 39,400 shares as a grant or award · Granted 78,700 Stock Options (right to buy)

17 Jul 2026 8-K: Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure

SOUTH SAN FRANCISCO, Calif., July 17, 2026 -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform...

07 Jul 2026 8-K: Other Events

Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine

06 Jul 2026 DEFINITIVE ADDITIONAL MATERIALS
02 Jul 2026 DEFINITIVE ADDITIONAL MATERIALS
02 Jul 2026 DFAN14A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support